Lixumistat acetate

• CAT Number: I029233
• CAS Number: 1422365-94-3
• Molecular Formula: C15H20F3N5O3
• Molecular Weight: 375.35
• Purity: ≥95%
• Synonyms: acetic acid;N’-[N’-[4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide
• IUPAC Name: acetic acid;N'-[N'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide
• InChI: InChI=1S/C13H16F3N5O.C2H4O2/c14-13(15,16)22-10-5-3-9(4-6-10)19-11(17)20-12(18)21-7-1-2-8-21;1-2(3)4/h3-6H,1-2,7-8H2,(H4,17,18,19,20);1H3,(H,3,4)
• InChIKey: AGFDCTOLSXWRDZ-UHFFFAOYSA-N
• SMILES: CC(=O)O.C1CCN(C1)/C(=N/C(=NC2=CC=C(C=C2)OC(F)(F)F)N)/N

Lixumistat acetate（Cat No.:I029233）is a small-molecule inhibitor designed to target hypoxia-inducible factor (HIF) prolyl hydroxylases, enzymes that regulate cellular oxygen sensing. By blocking these enzymes, lixumistat stabilizes HIF, enhancing transcription of genes involved in erythropoiesis and cellular adaptation to low oxygen. The acetate form improves stability and formulation for experimental use. Researchers explore lixumistat acetate in contexts such as anemia, ischemia, and metabolic disorders, where hypoxia signaling plays a central role. Its mechanism provides insights into oxygen homeostasis and therapeutic strategies for oxygen-related diseases.